Kotak Institutional Equities has reaffirmed its "Reduce" rating on Dr. Reddy's Laboratories following a reported miss in the company's profit margins. The financial services firm cited concerns over the pharmaceutical company's performance metrics, which did not meet market expectations. This decision reflects Kotak's assessment of the stock's potential for growth in the current economic climate. Investors are advised to consider this rating when evaluating their positions in Dr. Reddy's stock.
Related Articles
Don't miss out on breaking stories and in-depth articles.